Laniquidar
Alternative Names: R-101933Latest Information Update: 20 Sep 2006
At a glance
- Originator Janssen L.P.; Jules Bordet Institute
- Class Benzazepines; Quinolines
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Breast cancer; Solid tumours
Most Recent Events
- 20 Sep 2006 No development reported - Phase-II for Breast cancer in Europe (IV-infusion)
- 20 Jul 2006 No development reported - Phase-I for Solid tumours in Belgium (IV-infusion)
- 27 Jun 2000 A study has been added to the adverse events, pharmacokinetics, drug interactions and Cancer therapeutic trials sections